|
1
|
D’Cruz DP, Khamashta MA and Hughes GR:
Systemic lupus erythematosus. Lancet. 369:587–596. 2007.
|
|
2
|
Parker BJ and Bruce IN: High dose
methylprednisolone therapy for the treatment of severe systemic
lupus erythematosus. Lupus. 16:387–393. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wallace DJ: Advances in drug therapy for
systemic lupus erythematosus. BMC Med. 29:772010. View Article : Google Scholar
|
|
4
|
Barnes PJ: Mechanisms and resistance in
glucocorticoid control of inflammation. J Steroid Biochem Mol Biol.
120:76–85. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsujimura S, Saito K, Nakayamada S, Nakano
K and Tanaka Y: Clinical relevance of the expression of
P-glycoprotein on peripheral blood lymphocytes to steroid
resistance in patients with systemic lupus erythematosus. Arthritis
Rheum. 52:1676–1683. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo
J and Llorente L: P-glycoprotein in autoimmune diseases. Autoimmun
Rev. 3:188–192. 2004. View Article : Google Scholar
|
|
7
|
Hochberg MC: Updating the American College
of Rheumatology revised criteria for the classification of systemic
lupus erythematosus (letter). Arthritis Rheum. 40:17251997.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gladman DD, Ibañez D and Urowitz MB:
Systemic lupus erythematosus disease activity index 2000. J
Rheumatol. 29:288–291. 2002.PubMed/NCBI
|
|
9
|
Yee CS, Farewell VT, Isenberg DA, et al:
The use of Systemic Lupus Erythematosus Disease Activity Index-2000
to define active disease and minimal clinically meaningful change
based on data from a large cohort of systemic lupus erythematosus
patients. Rheumatology (Oxford). 50:982–988. 2011. View Article : Google Scholar
|
|
10
|
Feng X, Wu H, Grossman JM, et al:
Association of increased interferon-inducible gene expression with
disease activity and lupus nephritis in patients with systemic
lupus erythematosus. Arthritis Rheum. 54:2951–2962. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Petri M, Kim MY, Kalunian KC, et al:
Combined oral contraceptives in women with systemic lupus
erythematosus. N Engl J Med. 353:2550–2558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
de la Fuente H, Baranda L, Hernández MI,
et al: Lack of involvement of P-glycoprotein (P-gp) in pemphigus
patients with poor response to steroid therapy. J Dermatol Sci.
28:219–226. 2002.PubMed/NCBI
|
|
13
|
Grishanova AY, Melnikova EV, Kaledin VI,
Nikolin VP and Lyakhovich VV: Possible role of P-glycoprotein in
cyclophosphamide resistance of transplanted mouse RLS
lymphosarcoma. Bull Exp Biol Med. 139:611–614. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang J, Figurski M, Shaw LM and Burckart
GJ: The impact of P-glycoprotein and Mrp2 on mycophenolic acid
levels in mice. Transpl Immunol. 19:192–196. 2008.(In English and
Russian).
|
|
15
|
Li J, Liu P, Mao H, Wanga A and Zhang X:
Emodin sensitizes paclitaxel-resistant human ovarian cancer cells
to paclitaxel-induced apoptosis in vitro. Oncol Rep.
21:1605–1610. 2009.PubMed/NCBI
|
|
16
|
Guiducci C, Gong M, Xu Z, Gill M, et al:
TLR recognition of self nucleic acids hampers glucocorticoid
activity in lupus. Nature. 465:937–941. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsujimura S, Saito K, Tokunaga M, et al:
Overcoming treatment unresponsiveness mediated by P-glycoprotein
overexpression on lymphocytes in refractory active systemic lupus
erythematosus. Mod Rheumatol. 15:28–32. 2005. View Article : Google Scholar
|
|
18
|
Foote A, Briganti EM, Kipen Y, et al:
Macrophage migration inhibitory factor in systemic lupus
erythematosus. J Rheumatol. 31:268–273. 2004.PubMed/NCBI
|
|
19
|
Hoi AY, Hickey MJ, Hall P, Yamana J, et
al: Macrophage migration inhibitory factor deficiency attenuates
macrophage recruitment, glomerulonephritis, and lethality in
MRL/lpr mice. J Immunol. 177:5687–5696. 2006. View Article : Google Scholar
|
|
20
|
Li X, Zhang FS, Zhang JH and Wang JY:
Negative relationship between expression of glucocorticoid receptor
alpha and disease activity: glucocorticoid treatment of patients
with systemic lupus erythematosus. J Rheumatol. 37:316–321. 2010.
View Article : Google Scholar
|
|
21
|
Callaghan R, Crowley E, Potter S and Kerr
ID: P-glycoprotein: so many ways to turn it on. J Clin Pharmacol.
48:365–378. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wasilewska A, Zoch-Zwierz W, Pietruczuk M
and Zalewski G: Expression of P-glycoprotein in lymphocytes from
children with nephrotic syndrome, depending on their steroid
response. Pediatr Nephrol. 21:1274–1280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Barnes PJ and Adcock IM: Glucocorticoid
resistance in inflammatory diseases. Lancet. 373:1905–1917. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Farrell RJ and Kelleher D: Glucocorticoid
resistance in inflammatory bowel disease. J Endocrinol.
178:339–346. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tsujimura S, Saito K, Nakayamada S and
Tanaka Y: Etanercept overcomes P-glycoprotein-induced drug
resistance in lymphocytes of patients with intractable rheumatoid
arthritis. Mod Rheumatol. 20:139–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maillefert JF, Maynadie M, Tebib JG, et
al: Expression of the multidrug resistance glycoprotein 170 in the
peripheral blood lymphocytes of rheumatoid arthritis patients. The
percentage of lymphocytes expressing glycoprotein 170 is increased
in patients treated with prednisolone. Br J Rheumatol. 35:430–435.
1996. View Article : Google Scholar
|
